NADAC acquisition cost data for BYETTA 5 MCG DOSE PEN INJ. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00310651201 | $641.27 | 2022-01-01 | Rx |
| 00310651201 | $641.27 | 2022-01-01 | Rx |
| 00310651201 | $641.27 | 2022-01-01 | Rx |
| 00310651201 | $641.27 | 2022-01-01 | Rx |
| 00310651201 | $641.27 | 2022-01-01 | Rx |
| 00310651201 | $641.27 | 2022-01-01 | Rx |
| 00310651201 | $641.27 | 2022-01-01 | Rx |
| 00310651201 | $641.27 | 2022-01-01 | Rx |
| 00310651201 | $641.27 | 2022-01-01 | Rx |
| 00310651201 | $641.27 | 2022-01-01 | Rx |
Generic: Exenatide | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $61.4M | 52,880 | 11,574 | $375.13 |
| 2020 | $47.7M | 39,793 | 8,494 | $379.71 |
| 2021 | $38.0M | 28,346 | 6,282 | $409.55 |
| 2022 | $27.5M | 19,590 | 4,685 | $422.17 |
| 2023 | $20.6M | 14,042 | 3,396 | $442.15 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| Ohio | $1.7M | 1,114 | 280 |
| California | $1.4M | 1,014 | 242 |
| Texas | $1.4M | 908 | 233 |
| New York | $1.3M | 869 | 211 |
| Florida | $1.3M | 899 | 210 |
| Michigan | $1.1M | 679 | 187 |
| Pennsylvania | $720.6K | 487 | 127 |
| New Jersey | $716.0K | 430 | 106 |
| Illinois | $688.4K | 474 | 115 |
| Washington | $643.2K | 453 | 116 |
| North Carolina | $600.0K | 411 | 93 |
| Missouri | $593.0K | 446 | 104 |
| Indiana | $567.5K | 369 | 92 |
| Georgia | $551.0K | 385 | 86 |
| Tennessee | $547.7K | 445 | 104 |
| Colorado | $518.5K | 334 | 91 |
| Massachusetts | $483.3K | 302 | 80 |
| Minnesota | $434.5K | 299 | 65 |
| Arizona | $423.7K | 343 | 85 |
| Wisconsin | $402.8K | 278 | 76 |
| South Carolina | $394.0K | 298 | 63 |
| Kentucky | $343.4K | 216 | 52 |
| Virginia | $338.9K | 229 | 55 |
| Oregon | $281.0K | 162 | 42 |
| Maryland | $253.9K | 152 | 38 |
| Alabama | $235.5K | 142 | 37 |
| Connecticut | $202.6K | 111 | 34 |
| Louisiana | $196.5K | 168 | 41 |
| Iowa | $183.6K | 140 | 33 |
| Idaho | $171.2K | 136 | 32 |
| New Mexico | $166.2K | 106 | 29 |
| Arkansas | $156.2K | 110 | 26 |
| Utah | $153.8K | 84 | 29 |
| Mississippi | $145.7K | 128 | 25 |
| Maine | $142.3K | 96 | 21 |
| Kansas | $141.9K | 113 | 25 |
| New Hampshire | $135.5K | 72 | 21 |
| Oklahoma | $131.9K | 104 | 26 |
| Vermont | $111.2K | 63 | 17 |
| Nevada | $109.9K | 62 | 20 |
| Delaware | $92.5K | 51 | 17 |
| West Virginia | $90.9K | 57 | 20 |
| Nebraska | $90.1K | 69 | 13 |
| Hawaii | $60.3K | 35 | N/A |
| Rhode Island | $55.3K | 48 | N/A |
| Montana | $47.0K | 33 | N/A |
| Alaska | $39.8K | 21 | N/A |
| District of Columbia | $32.2K | 21 | N/A |
| North Dakota | $28.5K | 13 | N/A |
| Puerto Rico | $25.4K | 24 | N/A |
| Wyoming | $24.5K | 29 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.